Cancer Care · global
Personalized Cancer Vaccine Reports Phase 3 Success: Risk of Recurrence or Death After Melanoma Surgery Reduced by 42%
Merck and Moderna’s personalized mRNA therapy offers melanoma patients additional protection beyond postoperative immunotherapy. Two-year recurrence-free survival rates differed by 12.2 percentage points, but longer follow-up is needed to determine whether the treatment extends life.
After melanoma is surgically removed, preventing the cancer from returning is the next challenge patients face. Phase 3 trial results released by Merck and Moderna show that adding the personalized mRNA cancer vaccine intismeran autogene to postoperative immunotherapy can further reduce the risk of recurrence or death, providing evidence from a large randomized trial for a treatment tailored to the characteristics of each patient’s tumor.
The data were originally scheduled for presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, but an early leak prompted the two companies to release them on October 22. According to Fierce Biotech, ESMO confirmed that an embargo breach had occurred; Moderna subsequently stated in an October 24 update that the results had been presented at the congress. Clinically, the central question is how much additional protection the vaccine can offer on top of existing treatment.
The global randomized, double-blind trial, named INTerpath-001, enrolled 1,137 patients with stage IIB to IV cutaneous melanoma whose tumors had been completely resected. Participants were assigned in a two-to-one ratio to receive intismeran plus the anti-PD-1 drug pembrolizumab (Keytruda), or placebo plus pembrolizumab. After a median follow-up of 24.6 months, the combination reduced the risk of recurrence or death by 42%; the two-year recurrence-free survival rate was 82.2%, compared with 70.0% in the control group, a difference of 12.2 percentage points. The 42% figure refers to the relative reduction in risk during follow-up and should not be interpreted as meaning that an additional 42% of patients remained free of recurrence.
Whether the cancer spreads to distant organs is another important measure. The combination reduced the risk of distant metastasis or death by 38%, with a two-year distant metastasis-free survival rate of 88.5%, compared with 80.2% in the control group. However, overall survival data remain immature, so these results cannot yet establish whether patients live longer, and reduced recurrence cannot be directly equated with a cure.
Intismeran, also known as V940 or mRNA-4157, is a personalized cancer vaccine for therapeutic use. Researchers compare genetic information from patients’ tumor and normal samples, select up to 34 tumor-specific neoantigens, and encode them in mRNA with the aim of directing T cells to recognize cancer cells; pembrolizumab blocks PD-1 signaling that inhibits T-cell activity. Moderna said that personalized formulations were successfully manufactured for more than 99% of patients assigned to receive intismeran in the trial, but this manufacturing success rate does not mean that the same proportion of patients benefited from treatment.
How the data are analyzed also affects the efficacy figures. Moderna additionally noted that a prespecified sensitivity analysis, which excluded patients who did not receive any dose of their assigned vaccine or placebo, showed a 49% reduction in the risk of recurrence or death. This provides additional insight into the results, but the primary interpretation should still be based on the analysis covering all randomized patients, which showed a 42% risk reduction.
On safety, grade 3 to 5 treatment-related adverse events occurred in 14.2% of the combination group and 13.4% of the control group; common symptoms in the combination group included fever, injection-site pain, and fatigue. The two companies said that no new safety signals were identified and that they had contacted regulatory authorities about the results. The therapy remains investigational; current evidence supports a benefit in reducing recurrence after surgery in specific melanoma patients. Whether patients with other cancer types can benefit, and what long-term survival outcomes will be, remain questions for further research.